“We are on the cusp of a true revolution in biology, including how we research and develop new therapies, offering a real chance to transform how we treat patients and address the burden of disease.”
Robert A. Bradway is the CEO and Chairman of Amgen. Under his leadership, Amgen has advanced its portfolio of medicines for cancer, heart disease, migraine, osteoporosis, and autoimmune disorders, and invested in industry-leading capabilities and research for novel therapies. He is the former President, Chief Operating Officer, Chief Financial Officer, and Vice President of Operations Strategy.
He is also the Chairman of the CEO Roundtable on Cancer and a member of the American Heart Association CEO Roundtable, the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Board of Directors of The Boeing Company, and the Board of Trustees of the University of Southern California (USC), where he serves on the Advisory Board of the Leonard D. Schaeffer Center for Health Policy and Economics.
Bradway received his B.S. in biology from Amherst College and his M.B.A. from Harvard University. Prior to joining Amgen, he was the Managing Director at Morgan Stanley, where he managed the firm’s banking department and corporate finance activities in Europe.